Romanian Industry Starts Recovery

4 June 1995

Romanian pharmaceutical production in 1994 was still only 83% of the 1989 production figure, reports the daily newspaper Curierul National. The industry employed 9,888 people last year and drug exports were worth $40 million. Average profitability in the sector is said to be 16.5%.

A wide-ranging restructuring program is underway to provide domestically at least 65% of the country's drug requirements by the year 2000. Last year, the industry reportedly produced 40%. Curierul national says the program will cost about $231 million. Plans for the privatization of the industry include the sale of shares by tender for a minimum 20% to western companies and cooperation with foreign firms to import new technologies and to establish a strong financial base for the industry. Joint ventures with major multinationals are also envisaged.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight